Ann: DurAVR THV Featured Prominently During TVT 2021, page-12

HI Phantom, anybody would be hard put to discount the actual progress this IP has made, it has gone beyond company ‘spiel’ once it started becoming independently endorsed by experts in this field.

That there have been several great announcements and with Anteris emphatically highlighting that it is not a case of IF but WHEN this IP progresses to the next level you would have to wonder why the sp still languishes.

Problem is what?, next to no attention on what funding is needed for this company to maximise its IP to such time it can gain maximum return for its shareholders, bearing in mind the truism; the further it is developed the more it’s worth.

With FDA approval the sp needs to go beyond the usual ‘pump and dump’, major aim should be the ability of the company to raise at way higher levels.

Not sure if FDA approval will bring out a inked up deal in enough of a timeframe to relieve the continual pressure of fund raising in the interim.

Future funding via conversion of $8 options will be what amount?, SB participation?, SIO?, the agenda of the latter revealed if they do take up?

Imo , not advice.